Cargando…

Electronic medical records-based retrospective, longitudinal, observational study to understand the patient management of benign prostatic hyperplasia with alpha-blockers monotherapy in Indian population

OBJECTIVE: The present retrospective study evaluates the effectiveness and tolerability of alpha-blockers as monotherapy in patients with benign prostatic hyperplasia associated with lower urinary tract symptoms (LUTS). MATERIALS AND METHODS: A total of 335 male patients >50 years were categorize...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gupta, Rahul, Trivedi, Sameer, Vaddi, Surya Prakash, Borgohain, Mrinal, Mittal, Rajan, Pandit, Sucheta, Mane, Amey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252785/ https://www.ncbi.nlm.nih.gov/pubmed/37304518 http://dx.doi.org/10.4103/ua.ua_114_21

Ejemplares similares

Prospective Factor Analysis of Alpha Blocker Monotherapy Failure in Benign Prostatic Hyperplasia
por: Hong, Kyoung Pyo, et al.
Publicado: (2010)

α-Blocker Monotherapy and α-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
por: Shin, Teak Jun, et al.
Publicado: (2012)

Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia
por: Moon, Hyong Woo, et al.
Publicado: (2018)

Effect of Shifting from Combination Therapy to Monotherapy of α-Blockers or 5α-Reductase Inhibitors on Prostate Volume and Symptoms in Patients with Benign Prostatic Hyperplasia
por: Kim, Hyoung Woo, et al.
Publicado: (2011)

Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study
por: Nishimura, Akihiko, et al.
Publicado: (2021)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Economic Evaluation of Combination Therapy Versus Monotherapy for Treatment of Benign Prostatic Hyperplasia in Hong Kong
por: Wu, David Bin-Chia, et al.
Publicado: (2018)

Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia
por: Odusanya, Benjamin O, et al.
Publicado: (2017)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Efficacy of Alpha Blocker Treatment According to the Degree of Intravesical Prostatic Protrusion Detected by Transrectal Ultrasonography in Patients with Benign Prostatic Hyperplasia
por: Park, Hee Young, et al.
Publicado: (2012)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
por: Cai, Tong, et al.
Publicado: (2020)

International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients
por: Nishimura, Akihiko, et al.
Publicado: (2022)

Evaluation of Effectiveness and Tolerability of Fondaparinux in the Management of Symptomatic Acute Coronary Syndrome: A Real-World Evidence-Based Study on an Indian Population
por: Dalal, Jamshed, et al.
Publicado: (2022)

Three-year outcome analysis of alpha 1-blocker naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan
por: Masumori, Naoya, et al.
Publicado: (2016)

Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia
por: Sicras-Mainar, Antoni, et al.
Publicado: (2017)

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study
por: Kwon, Se Yun, et al.
Publicado: (2020)

Effectiveness and Tolerability of Fondaparinux vs Enoxaparin in a Population of Indian Patients with Symptomatic Deep Vein Thrombosis: A Retrospective Real-World Study
por: Ramakrishna, Pinjala, et al.
Publicado: (2021)

Effectiveness of Telmisartan on Blood Pressure Control in Hypertensive Patients in India: A Real-World Retrospective Study from Electronic Medical Records
por: Khan, Mohammed Yunus, et al.
Publicado: (2021)

Comparing effects of alpha-blocker management on acute urinary retention secondary to benign prostatic hyperplasia: A systematic review and network meta-analysis
por: Gwon, Yong Nam, et al.
Publicado: (2023)

Personalized therapeutics of α(1)-blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
por: Zhu, Ling-ling, et al.
Publicado: (2015)

Benign Prostatic Hyperplasia
Publicado: (2015)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States
por: DerSarkissian, Maral, et al.
Publicado: (2016)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis
por: Kim, Hyun Jung, et al.
Publicado: (2017)

Is prostatic artery embolization a relevant treatment after a failed alpha-blocker monotherapy?
por: Lebdai, Souhil
Publicado: (2023)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study
por: Sidgiddi, Srinivas, et al.
Publicado: (2021)

Current Applications of Artificial Intelligence in Benign Prostatic Hyperplasia
por: Shah, Milap, et al.
Publicado: (2022)

Assessment of posterior urethra in benign prostatic hyperplasia and after its surgery
por: Agrawal, Vivek, et al.
Publicado: (2020)

Influence of Panax ginseng on Alpha-Adrenergic Receptor of Benign Prostatic Hyperplasia
por: Kim, Su Kang, et al.
Publicado: (2014)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Management of benign prostatic hyperplasia with silodosin
por: Yamanishi, Tomonori, et al.
Publicado: (2009)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_h57rqq30i61scrhv4juhrnd4cl